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Malaria, a tremendously successful pathogen that is responsible for more than 300 
million cases and 1 million deaths annually,
1 has had a large impact on the shape of the 
human genome. Malaria- selected mutations in human genes promote survival in areas 
where malaria is endemic. The parasite’s substantive effect on the human genome is due 
to its high prevalence in areas where it is endemic and its long history of coevolution with 
humans. Moreover, its marked genetic diversity, generated by its sexual stage, provides 
the organism with many opportunities to maximally adapt to host defenses and continue 
transmission. In this issue of the Journal, Ayi et al.
2 describe a polymorphism that is 
hypothesized to provide resistance to malaria infection.  
 
Why is the study of pathogen-selected host polymorphisms useful? It provides insight 
into naturally occurring mechanisms of host defense, which could be used to develop 
therapeutic agents to combat disease. Often, host polymorphisms occur in multiple genes, 
and their combined effect on resistance to disease presents an analytical challenge that 
requires the development of methods that can also be applied to other complex genetic 
scenarios. Finally, the role of host factors needs to be considered in the evaluation of 
therapeutic interventions and to refine models of pathogenesis.  
 
Defense against malaria has been ascribed to many polymorphisms that have been 
maintained over generations (thanks to selection) in the human genome.
3 Such protective 
polymorphisms are found in disparate genes that encode the cytokine response and 
erythrocyte proteins. The latter class of polymorphism hits close to home for the parasite: 
the erythrocyte is its most remarkable niche, where it finds shelter from host defenses and 
abundant substrates. The mechanisms of protection from this class of polymorphism are 
varied, ranging from inhibiting parasite growth to compromising the ability of the 
parasite to adhere to the microvasculature to promoting enhanced splenic clearance 
before the parasite can complete its life cycle.
4 Some studies suggest that there are 
additional unknown genetic polymorphisms that mediate disease outcome and that each 
genetic mutation accounts for a small epidemiologic effect.
5  
 
The study by Ayi et al. builds on the established association between pyruvate kinase 
deficiency and protection from disease in a mouse model of malaria.
6,7 The study shows 
that the extent of infection and replication of Plasmodium falciparum in vitro is 
significantly decreased in erythrocytes that are deficient in pyruvate kinase, as compared 
with that of normal human erythrocytes. Ring-stage parasites are less likely to invade 
pyruvate kinase–deficient erythrocytes than they are wild-type erythrocytes. Once 
infected, pyruvate kinase–deficient erythrocytes are more likely than wild-type cells to be 
cleared from the circulation by phagocytosis.  
 
Pyruvate kinase is a glycolytic enzyme required for energy production, allowing the 
erythrocyte to maintain structural integrity and function. Mutations in the pyruvate kinase 
gene (PKLR) alter protein function, resulting in nonspherocytic hemolytic anemia. Nearly 	 ﾠ 2	 ﾠ
200 different PKLR mutations are associated with pyruvate kinase deficiency; the degree 
of hemolysis and anemia varies markedly, depending on the mutation.
8  
 
A major criticism of many genetic association studies, both in malaria and other diseases, 
is a lack of biologic mechanism. The study by Ayi et al., in contrast, is a study of the 
biologic mechanism without direct observation of an association with disease in humans. 
Although the biologic mechanism is considered by some to be the gold standard, testing 
for a genetic association would have great value. It would clinch the case for a 
mechanism associated with pyruvate kinase deficiency in protecting against malaria. 
More extensive genetic sleuthing would probably yield information about the degree of 
protective advantage conferred by different mutations in PKLR in different populations. 
The strength of protection of PKLR alleles would serve as an excellent reference by 
which to evaluate new alleles in other genes associated with malaria resistance, in which 
biologic confirmation is lacking.  
 
More broadly, an examination of the action of selective pressure on pyruvate kinase 
could shed light on the history and mechanism of human resistance to malaria. 
Deficiency in glucose-6-phosphate dehydrogenase (G6PD), the other most common 
cause of nonspherocytic hemolytic anemia, also has biologic links to malaria resistance. 
Numerous mutations have been identified in G6PD,
9 many of which affect the level of 
enzymatic activity. However, despite the considerable genetic diversity in G6PD, it 
appears that a single mutation that causes G6PD deficiency (approximately 12% of 
enzyme activity) has been selected in many African populations
10 and is associated with 
malaria resistance. The study by Ayi et al. sets the stage for a case–control study to test 
for an association between PKLR polymorphisms and disease, as well as defining the 
global distribution of PKLR polymorphisms.  
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